A BILL 
To amend title XVIII of the Social Security Act to require 
PDP sponsors of a prescription drug plan under part 
D of the Medicare program that use a formulary to 
include certain generic drugs and biosimilar biological 
products on such formulary, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Ensuring Access to 
4
Lower-Cost Medicines for Seniors Act of 2021’’. 
5
02:44 Jun 08, 2021
H2846
2 
•HR 2846 IH
SEC. 2. REQUIREMENTS FOR PDP SPONSORS OF PRESCRIP-
1
TION DRUG PLANS UNDER PART D OF THE 
2
MEDICARE 
PROGRAM 
THAT 
USE 
3
FORMULARIES. 
4
(a) IN GENERAL.—Section 1860D–4(b)(3) of the So-
5
cial Security Act (42 U.S.C. 1395w–104(b)(3)) is amend-
6
ed by adding at the end the following new subparagraphs: 
7
‘‘(I) REQUIRED
INCLUSION
OF
CERTAIN 
8
GENERIC DRUGS AND BIOSIMILAR BIOLOGICAL 
9
PRODUCTS.— 
10
‘‘(i) IN GENERAL.—With respect to a 
11
plan year beginning on or after January 1, 
12
2022, the formulary shall include— 
13
‘‘(I) each covered generic drug 
14
for which the wholesale acquisition 
15
cost is less than the wholesale acquisi-
16
tion cost of the reference drug of such 
17
covered generic drug; and 
18
‘‘(II) each covered biosimilar bio-
19
logical product for which the whole-
20
sale acquisition cost is less than the 
21
wholesale acquisition cost of the ref-
22
erence biological product of such cov-
23
ered biosimilar biological product. 
24
‘‘(ii) PROHIBITION ON CERTAIN LIM-
25
ITS ON ACCESS.—The PDP sponsor offer-
26
02:44 Jun 08, 2021
H2846
3 
•HR 2846 IH
ing the prescription drug plan may not im-
1
pose limits on access to a covered generic 
2
drug required to be included on the for-
3
mulary under clause (i)(I) or a covered 
4
biosimilar biological product required to be 
5
included on the formulary under clause 
6
(i)(II), including through prior authoriza-
7
tion, utilization management, or step ther-
8
apy, that are more restrictive than any 
9
such limits imposed on access to the ref-
10
erence drug of such covered generic drug 
11
or reference biological product of such cov-
12
ered biosimilar biological product, respec-
13
tively, or that otherwise have the effect of 
14
giving preferred status to such reference 
15
drug or reference biological product over 
16
such covered generic drug or covered bio-
17
similar biological product, respectively. 
18
‘‘(iii) DEFINITIONS.—In this subpara-
19
graph and subparagraph (J): 
20
‘‘(I) COVERED
BIOSIMILAR
BIO-
21
LOGICAL
PRODUCT.—The term ‘cov-
22
ered biosimilar biological product’ 
23
means a covered part D drug that is 
24
02:44 Jun 08, 2021
H2846
4 
•HR 2846 IH
a biosimilar biological product (as de-
1
fined in section 1847A(c)(6)(H)). 
2
‘‘(II) 
COVERED
GENERIC 
3
DRUG.—The term ‘covered generic 
4
drug’ means a covered part D drug 
5
that is a drug described in section 
6
1860D–2(e)(1)(A) 
and 
approved 
7
under section 505(j) of the Federal 
8
Food, Drug, and Cosmetic Act. 
9
‘‘(III) REFERENCE
BIOLOGICAL 
10
PRODUCT.—The term ‘reference bio-
11
logical product’ has the meaning given 
12
such term in section 1847A(c)(6)(I). 
13
‘‘(IV) REFERENCE
DRUG.—The 
14
term ‘reference drug’ means, with re-
15
spect to a covered generic drug, the 
16
listed drug (as described in clause (i) 
17
of section 505(j)(2)(A) of the Federal 
18
Food, Drug, and Cosmetic Act) that 
19
is referred to in the abbreviated appli-
20
cation for such covered generic drug 
21
under such section. 
22
‘‘(V) WHOLESALE
ACQUISITION 
23
COST.—The term ‘wholesale acquisi-
24
02:44 Jun 08, 2021
H2846
5 
•HR 2846 IH
tion cost’ has the meaning given such 
1
term in section 1847A(c)(6)(B). 
2
‘‘(J) COST-SHARING
TIERING
REQUIRE-
3
MENTS WITH RESPECT TO COVERED GENERIC 
4
DRUGS AND COVERED BIOSIMILAR BIOLOGICAL 
5
PRODUCTS.— 
6
‘‘(i) GENERIC
DRUG
COST-SHARING 
7
TIER.—With respect to a plan year begin-
8
ning on or after January 1, 2022, the 
9
PDP sponsor offering the prescription 
10
drug plan shall— 
11
‘‘(I) have at least one cost-shar-
12
ing tier on the formulary that only in-
13
cludes covered generic drugs and cov-
14
ered biosimilar biological products; 
15
and 
16
‘‘(II) apply a cost-sharing re-
17
quirement with respect to each cost- 
18
sharing tier described in subclause (I) 
19
on the formulary that is meaningfully 
20
lesser than the lowest cost-sharing re-
21
quirement applicable with respect to 
22
any cost-sharing tier on such for-
23
mulary that includes a brand drug 
24
(referred to in this subparagraph as 
25
02:44 Jun 08, 2021
H2846
6 
•HR 2846 IH
the ‘lowest brand drug cost-sharing 
1
tier’). 
2
‘‘(ii) SPECIALTY GENERIC DRUG COST- 
3
SHARING
TIER.—With respect to a plan 
4
year beginning on or after January 1, 
5
2022, if the PDP sponsor offering the pre-
6
scription drug plan has a cost-sharing tier 
7
for specialty brand drugs on the formulary, 
8
the PDP sponsor shall— 
9
‘‘(I) have a cost-sharing tier on 
10
such formulary that only includes cov-
11
ered generic drugs and covered bio-
12
similar biological products— 
13
‘‘(aa) for which the whole-
14
sale acquisition cost is greater 
15
than a threshold specified by the 
16
Secretary; and 
17
‘‘(bb) with respect to which 
18
the reference drug for such a 
19
covered generic drug or the ref-
20
erence biological product for such 
21
a covered biosimilar biological 
22
product is either included on a 
23
cost-sharing tier on such for-
24
mulary with a cost-sharing re-
25
02:44 Jun 08, 2021
H2846
7 
•HR 2846 IH
quirement that is greater than 
1
the cost-sharing requirement ap-
2
plied under subclause (II), or ex-
3
cluded from such formulary; and 
4
‘‘(II) apply a cost-sharing re-
5
quirement with respect to the cost- 
6
sharing tier required for the for-
7
mulary under subclause (I) that is 
8
meaningfully lesser than the cost- 
9
sharing requirement applicable with 
10
respect to the cost-sharing tier for 
11
specialty brand drugs on such for-
12
mulary. 
13
‘‘(iii) PLACEMENT
OF
CERTAIN
GE-
14
NERIC
DRUGS
AND
BIOSIMILAR
BIOLOGI-
15
CAL
PRODUCTS.—Each covered generic 
16
drug and each covered biosimilar biological 
17
product required to be included on the for-
18
mulary under subparagraph (I)(i) shall be 
19
included either on a cost-sharing tier de-
20
scribed in clause (i)(I) or, if applicable, the 
21
cost-sharing tier required for the formulary 
22
under clause (ii)(I). 
23
‘‘(iv) DEFINITIONS.—In this subpara-
24
graph: 
25
02:44 Jun 08, 2021
H2846
8 
•HR 2846 IH
‘‘(I) BRAND
DRUG.—The term 
1
‘brand drug’ means a covered part D 
2
drug that is a drug described in sec-
3
tion 1860D–2(e)(1)(A) and approved 
4
under section 505(c) of the Federal 
5
Food, Drug, and Cosmetic Act. 
6
‘‘(II) MEANINGFULLY LESSER.— 
7
The 
term 
‘meaningfully 
lesser’ 
8
means— 
9
‘‘(aa) for purposes of sub-
10
clause (II) of clause (i), such a 
11
lesser cost-sharing requirement 
12
that the Secretary determines 
13
will likely significantly incentivize 
14
the utilization of covered generic 
15
drugs and covered biosimilar bio-
16
logical products on a cost-sharing 
17
tier described in subclause (I) of 
18
such clause on a formulary over 
19
covered part D drugs on the low-
20
est brand drug cost-sharing tier 
21
on such formulary; and 
22
‘‘(bb) for purposes of sub-
23
clause (II) of clause (ii), such a 
24
lesser cost-sharing requirement 
25
02:44 Jun 08, 2021
H2846
9 
•HR 2846 IH
that the Secretary determines 
1
will likely significantly incentivize 
2
the utilization of covered generic 
3
drugs and covered biosimilar bio-
4
logical products on the cost-shar-
5
ing tier required for the for-
6
mulary under subclause (I) of 
7
such clause over covered part D 
8
drugs on the cost-sharing tier for 
9
specialty brand drugs on such 
10
formulary. 
11
‘‘(III) 
SPECIALTY
BRAND 
12
DRUG.—The term ‘specialty brand 
13
drug’ means a brand drug for which 
14
the wholesale acquisition cost is great-
15
er than a threshold specified by the 
16
Secretary.’’. 
17
(b) CONFORMING AMENDMENT.—Section 1860D– 
18
2(b)(2)(B) of the Social Security Act (42 U.S.C. 1395w– 
19
102(b)(2)(B)) is amended by inserting before the period 
20
the following: ‘‘and section 1860D–4(b)(3)(J)’’. 
21
Æ 
02:44 Jun 08, 2021
H2846
